XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 25.65

+2.7%

Jan 30 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Thomas J Pittman who wrote (11231)	8/16/1999 5:34:00 PM
From: Thomas J Pittman	Read Replies (1) of 17367

.....focus has been on neuprex, but beginning to get a pipeline. Questions: Edmund Dedler (SAC capital) More detail on 'clinical benefit'? A) MUST stick to rules on disclosure. cant say anything. Will you have data at iccaac? Dont know? Sense of strength on numbers?? A) We could but is not in our interest to do so Q) Piper Jaffery What was endpoint prior to first eval A)mortality. in conjunction with FDA we decided to expand it to include morbidity. FDA expressed an interest in these results as well. Q: Was that ethical? A) we are comfortable to have modified the endpoint and still be ethical. Q: q about subpart e Q: when will we hear more A: meeting in october, why so long, they have to have 4 weeks to review

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next